A study by French health authorities has found Sanofi’s epilepsy drug Depakine (valproate) and its generics are linked with severe birth defects in up to 4,100 children in France since it was ...
Marketed in France as Depakine, it was found to carry a high risk of birth defects if taken by pregnant women. Sanofi denies wrongdoing and says it warned of the potential risks long ago.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback